Q-omics provides the consensus-scored MAPT-AS1 profile across patient tissues and cancer cell-line models. MAPT-AS1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MAPT-AS1 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, MAPT-AS1 RNA expression shows 14,208 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where MAPT-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAPT-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAPT-AS1 survival associations across molecular data types. MAPT-AS1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAPT-AS1 RNA expression–survival associations across cancer types. High MAPT-AS1 expression shows unfavorable associations in ESCA, TGCT and MESO, but favorable associations in KIRC, BRCA and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MAPT-AS1 RNA expression.
This table summarizes MAPT-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MAPT-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAPT-AS1 shows lower tumor expression in COAD, HNSC, KICH and STAD and higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher MAPT-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.317, t-test p = .001).
This table shows molecular features associated with MAPT-AS1 in patient tissues and cancer cell lines. In patient samples, MAPT-AS1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
